Skip Nav Destination
Issues
1 June 2014
-
Cover Image
Cover Image
An aberrant crypt foci (ACF) obtained from the proximal (right) colon shows a distinct serrated morphology similar to that observed in human serrated adenomas (cover image). ACF are considered to represent the earliest macroscopically identifiable abnormality within the colorectal mucosa and can be routinely identified during high-definition chromoendoscopy. Importantly, these small lesions often harbor somatic mutations to colorectal cancer-associated oncogenes, including activating mutations to KRAS and BRAF. Furthermore, ACF provide valuable insight into the earliest stages of colorectal carcinogenesis andmay serve as a surrogate marker of future cancer risk. For more information, see the article by Drew and colleagues on page 823. - PDF Icon PDF LinkTable of Contents
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Highlights
Review
Rapid Impact
Cell Cycle and Senescence
Cell Death and Survival
Chromatin, Gene, and RNA Regulation
Dual Promoter Usage as Regulatory Mechanism of let-7c Expression in Leukemic and Solid Tumors
Andrea Pelosi; Silvia Careccia; Giulia Sagrestani; Simona Nanni; Isabella Manni; Valeria Schinzari; Joost H.A. Martens; Antonella Farsetti; Hendrik G. Stunnenberg; Maria Pia Gentileschi; Donatella Del Bufalo; Ruggero De Maria; Giulia Piaggio; Maria Giulia Rizzo
Oncogenes and Tumor Suppressors
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer
Amy S. Farrell; Brittany Allen-Petersen; Colin J. Daniel; Xiaoyan Wang; Zhiping Wang; Sarah Rodriguez; Soren Impey; Jessica Oddo; Michael P. Vitek; Charles Lopez; Dale J. Christensen; Brett Sheppard; Rosalie C. Sears
Signal Transduction
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.